Growth ConcernsAnalysts believe the EU is unlikely to be a major growth driver for Madrigal, at least in the near term, due to slower European launch dynamics and pricing constraints.
Market CompetitionSome investors are concerned about Rezdiffra losing market share to the more visible and popularized Wegovy treatment.
Pricing ConstraintsCost-conscious single payer systems in the EU may not reimburse Rezdiffra near its current annual Wholesale Acquisition Cost of approximately $49k.